Company intelligence / Profile preview
Cytovation
Bergen, Norwaycytovation.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Cytovation’s lead candidate, CyPep‑1/CY‑101, has demonstrated a dual mode of action—directly lysing tumor cells and inducing an immune response through in situ vaccination. The company’s approach aims to overcome resistance mechanisms associated with the Wnt/β-catenin pathway. Early clinical data support safety and initial efficacy signals across multiple solid tumor types; further results are pending from ongoing trials targeting ACC, HCC, CRC, and other β-catenin-driven cancers.
- Therapeutic areas
- OncologyDermatology
- Modalities
- Synthetic peptides (notably bifunctional and engineered peptides)Immunotherapy agents
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Cytovation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cytovation.